VR Mind and VR Mind+ Intervention
VR Mind™ and VR Mind +™ Intervention - Randomized, Open Label, Single Masking, Parallel Group Clinical Trial
Study Overview
Status
Conditions
Detailed Description
In this study, investigators will test the software developed by Tomorrow Sp. z o. o., named VR Mind and VR Mind+. The software utilizes the concept of virtual reality exposure therapy to treat social anxiety disorder. The aim of the study is to assess the safety and efficacy of VR Mind and VR Mind + interventions.
The research consists of fourteen sessions. The first and the last session will be dedicated to participant assessment. Subsequent sessions 2-13 will be performed according to the therapy protocol for each arm. Control group of participants (active comparative arm) will receive standard treatment for social anxiety disorder - cognitive behavioral therapy based on the protocol developed by the Principal Investigator [protocol adapted from the approach of Clark and Wells (Mayo-Wilson, Dias, Mavranezouli, 2014)]. Experimental group 1 will receive cognitive behavioral therapy with exposure in virtual environment. Experimental group 1 and control group were designed to be as similar as possible, with the exception of the modality for the delivery of exposure. All treatment session will be led by licensed therapist.
Participants of the experimental group 2 will independently conducts the self-therapy process. The intervention will consist of 12 therapeutic sessions. At each of the 12 sessions, the participant will selects a specific scenario of social situations that arouse fear (e.g. public speaking, job interview or other situations from everyday life).
Because of the risk of simulator sickness (e.g., headaches, nausea), exposure trials will last no longer than 20 minutes for each session.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Warsaw, Poland, 03-913
- Tomorrow Sp. z o. o.
-
Warsaw, Poland
- Gabinet Psychoterapii
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed DSM-IV-TR criteria for Social Anxiety Disorder (SAD).
- Signing informed consent
- Unchanged doses of psychotropic medications within 3 months prior to baseline assessment and no change is anticipated
Exclusion Criteria:
- occurrence of SAD symptoms inconsistent with DSM-IV-TR criteria and with psychiatric interview (SCID-I; Structured Clinical Interview)
- psychosis,
- bipolar disorder,
- mental retardation
- pregnancy,
- drug addiction,
- alcohol addiction,
- psychoactive substances addiction,
- participating in the experimental session while intoxicated
- (current) neurological treatment of chronic disease of central nervous system,
- epilepsy,
- paroxysmal vertigo,
- presence of suicidal thoughts, tendencies or attempts,
- participant is taking drugs from benzodiazepine group, other sedatives, narcotic drugs
- current CBT treatment for Social Anxiety Disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1: VR Mind+
Virtual Reality Exposure Therapy VR Mind+
|
Virtual Reality Exposure Self-Therapy led by a participant
|
|
Experimental: Group 2: VR Mind
Virtual Reality Exposure Therapy VR Mind
|
Treatment with Virtual Reality Exposure Therapy led by a therapist
|
|
Active Comparator: Control group: CBT
Cognitive Behavioral Therapy
|
Standard treatment for social phobia led by a therapist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy: Liebowitz Social Anxiety Scale - Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987)
Time Frame: change from baseline: Pre-treatment at session 1, to session 9 (5 weeks) and to post-treatment at session 14 (7 weeks)
|
The scale is composed of 24 items, depicting various social situations.
For each item, participants assess their fear (from 1 - "No fear" to 4 - "Severe") and avoidance (from 1 - "Never" to 4 - "Usually").
LSAS has 3 scores, summing the results for particular items - fear (0-72), avoidance (0-72) and total score (0-144).
|
change from baseline: Pre-treatment at session 1, to session 9 (5 weeks) and to post-treatment at session 14 (7 weeks)
|
|
Safety: Occurrence and severity of Simulator Sickness - Simulator Sickness Questionnaire (SSQ; Kennedy, Lane, Berbaum, Lilienthal, 1993)
Time Frame: Change from session to session with virtual reality exposure: at session 1, session 7 (4 weeks), session 8 (4 weeks), session 10 (5 weeks), session 11 (6 weeks) and session 12 (6 weeks)
|
Simulator sickness is expected adverse effect of the VR.Total SSQ score equal to or higher than 10 will be used as a preliminary cut-off for simulator sickness (Balk et al., 2013). Individual scores will be corrected for baseline (pre-VR) symptom severity. Only items with a pre-VR - post-VR increase will contribute to a final SSQ score. All post-intervention SSQ scores >10 will be analyzed further for its association with study drop-outs and other intervention required. The adverse effect will be classified as:
Some of the symptoms of anxiety may produce similar side effects as a simulator sickness. The results obtained in this case will be false positive. Therefore assessment of side effects for each case will be verified if the increase in SSQ score was triggered by rapid relapse of phobia symptoms. |
Change from session to session with virtual reality exposure: at session 1, session 7 (4 weeks), session 8 (4 weeks), session 10 (5 weeks), session 11 (6 weeks) and session 12 (6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Global Impression
Time Frame: Pre-treatment at session 1
|
Clinical Global Impression (CGI; Guy, 1976) - is a single item, 7 point scale used by clinicians to assess the severity of illness, where 1 is labeled as "Normal, not at all ill" and 7 is labeled as "Among the most extremely ill patients".
|
Pre-treatment at session 1
|
|
Clinician Global Impressions of Improvement
Time Frame: Post-treatment, approximately 7 weeks after initial session
|
Global measure of change in severity of symptoms, ranging from 1 labeled as " Very much improved" to 7 labeled as "Very much worse".
|
Post-treatment, approximately 7 weeks after initial session
|
|
Patient Global Impression
Time Frame: Pre-treatment at session 1
|
Patient Global Impression - is a single item, 4 point scale used by patients to assess their impression of severity of their illness and quality of their functioning in everyday life, where 1 is labeled as "Normal" and 4 is labeled as "Severe".
|
Pre-treatment at session 1
|
|
Patient Global Impressions of Improvement
Time Frame: Post-treatment, approximately 7 weeks after initial session
|
Global measure of change in severity of symptoms, where 1 is labeled as "No change" and 7 is labeled as " Very much improved ".
|
Post-treatment, approximately 7 weeks after initial session
|
|
Beck Depression Inventory
Time Frame: Pre-treatment at session 1 to post-treatment at session 14 (7 weeks)
|
A 21-question multiple-choice self-report inventory for measuring the severity of depression. Each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs used differ from the original: 0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression |
Pre-treatment at session 1 to post-treatment at session 14 (7 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Units of Distress
Time Frame: Change from session to session with virtual reality exposure during the course of six weeks
|
Subjective Units of Distress (SUD) SUD is a subjective measure of perceived fear in certain situation.
The scale range is from 0 ("Totally relaxed) to 100 ("Highest distress/fear/anxiety/discomfort that you have ever felt").
|
Change from session to session with virtual reality exposure during the course of six weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Paweł Mierzejewski, prof., Scientific Council
- Study Director: Przemysław Bieńkowski, prof., Scientific Council
- Study Director: Tadeusz Parnowski, prof., Scientific Council
- Study Director: Sławomir Murawiec, PH.D., Scientific Council
- Principal Investigator: Izabela Stefaniak, M.D., Scientific Council
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRR/POIR.01.01.01-00-0636
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.